Functional experiments further demonstrated that TPX2 promotes tumor cell proliferation, migration, and resistance to apoptosis.<h4>Conclusion</h4>This study identifies a proliferation-driven immune suppression program in LUAD, establishes DPIS as a robust and clinically applicable framework for immune stratification, and highlights TPX2 as a potential therapeutic target for overcoming immune resistance. This evidence concerns the gene TPX2 and neoplasm.